Please login to the form below

Not currently logged in
Email:
Password:

Kalina Scott joins Switzerland's Polyphor

Moves from Bank am Bellevue to take up CFO role at the pharma company

Switzerland-based pharmaceutical company Polyphor has appointed Kalina Scott as its chief financial officer.

She has over 20 years’ experience in mergers, acquisitions, capital markets and private placements particularly in the healthcare field, and has joined the privately-owned company from Bank Am Bellevue where she served as managing director.

She said: “I am honoured and very excited about the opportunity to support Polyphor in its goal to become the leader in the development of powerful therapies that help patients to improve their lives and bring value to shareholders.”

During her career Scott has worked with a number of corporate companies and medical groups including Molecular Partners, Cassiopea, Galenica Santé, Mathys Medical and Sulzer Medica.

Giacomo Di Nepi, CEO of Polyphor, said: “I am very pleased that Kalina has decided to join Polyphor.

“Her extensive experience in the finance area, combined with her transaction-based expertise in healthcare and her broad network will help grow Polyphor and support our corporate strategy and transformation.”

Scott succeeds Alain Schaffter who will leave Polyphor to take on a what the company said would be a new challenge.

7th June 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics